New pill aims to control hepatitis b and boost immune response
Disease control
Recruiting now
This phase 3 study tests azvudine tablets in 120 people with chronic hepatitis B. The drug works by both fighting the virus and activating the immune system. Researchers will monitor viral load, liver function, and immune activity over 12 months to see if azvudine can help achiev…
Phase: PHASE3 • Sponsor: Zhigang Ren • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC